Science & Research | May 8th, 2020
UK-based RECOVERY Trial on COVID-19 treatments enrolling children as of 11 May
Researchers and medical experts from around the world have suggested varying treatments to tackle the COVID-19 outbreak. Unfortunately, at this stage, there is no consensus on if any of these are more effective compared to standard hospital care.
The RECOVERY Trial based at Oxford University will kick off by testing several proposed treatments for adults (while children will have different medications). These include:
- Lopinavir-Ritonavir (commonly used in the treatment of HIV)
- Low-dose Dexamethasone (a type of steroid, which finds application in a range of conditions commonly to ease inflammation).
- Hydroxychloroquine (related to an anti-malarial drug)
- Azithromycin (a frequently used antibiotic)
- Tocilizumab (an anti-inflammatory treatment administered by injection)
As of Monday, 11 May, the trial will start enrolling children and infants down to the day of birth. This is of vital importance so as to be able to formulate safe and effective treatments for the younger population, too.
ESPR President Prof Charles Roehr has taken the role of neonatal lead. If you would like to get in touch with him regarding the RECOVERY Trial, please contact the ESPR secretariat via firstname.lastname@example.org.
For more information on the RECOVERY study of multiple potential treatments, please klick here: www.recoverytrial.net.